{"id":14991,"date":"2011-12-29T20:45:24","date_gmt":"2011-12-30T01:45:24","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=14991"},"modified":"2011-12-29T20:45:24","modified_gmt":"2011-12-30T01:45:24","slug":"jj-applies-for-acs-indication-for-rivaroxaban-xarelto","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/12\/29\/jj-applies-for-acs-indication-for-rivaroxaban-xarelto\/","title":{"rendered":"J&#038;J Applies for ACS Indication for Rivaroxaban (Xarelto)"},"content":{"rendered":"<p>Based on the promising results of\u00a0<a title=\"ATLAS ACS 2-TIMI 51: Rivaroxaban Benefits Low-Risk ACS Patients\" href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/atlas-acs-2-timi-51-rivaroxaban-benefits-low-risk-acs-patients\/\">the recently published ATLAS ACS 2 TIMI 51 trial<\/a>, Johnson &amp; Johnson has submitted a supplemental new drug application to the FDA for the approval of rivaroxaban (Xarelto) to reduce the risk of thrombotic cardiovascular events in ACS patients.<\/p>\n<p>Following a succession of failed trials, ATLAS was the first trial to show a benefit in ACS with an anticoagulant. One key difference highlighted by many experts was the low dose of rivaroxaban used in the trial. In\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/voices\/roundtable-two-trials-two-anticoagulants-many-implications\/\">remarks published on CardioExchange<\/a>,\u00a0Samuel Goldhaber said that the trial \u201cchanges forever the way we\u2019ll think about the pathophysiology of ACS and the way we\u2019ll manage patients with STEMI, NSTEMI, or unstable angina.\u201d<\/p>\n<p>Link to <a title=\"Janssen_Xarelto\" href=\"http:\/\/www.prnewswire.com\/news-releases\/janssen-research--development-submits-application-to-us-fda-for-xarelto-rivaroxaban-to-reduce-secondary-cardiovascular-events-in-patients-with-acute-coronary-syndrome-136369578.html\" target=\"_blank\">press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Based on the promising results of\u00a0the recently published ATLAS ACS 2 TIMI 51 trial, Johnson &amp; Johnson has submitted a supplemental new drug application to the FDA for the approval of rivaroxaban (Xarelto) to reduce the risk of thrombotic cardiovascular events in ACS patients. Following a succession of failed trials, ATLAS was the first trial [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,1],"tags":[239,1009,1087,366,990],"class_list":["post-14991","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-general","tag-acs","tag-atlas-acs","tag-nda","tag-rivaroxaban","tag-xarelto"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/14991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=14991"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/14991\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=14991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=14991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=14991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}